VPC-14228

VPC-14228 is an inhibitor that selectively targets androgen receptor DNA binding domain (AR-DBD) . VPC-14228 inhibits the interaction between AR and DNA, thereby blocking AR-mediated transcriptional activation. VPC-14228 does not rely on nuclear localization inhibition, but rather inhibits the activity of full-length AR and splice variant AR-V7 by interfering with AR binding to chromatin. And VPC-14228 has high selectivity for other nuclear receptors such as ER and PR. VPC-14228 can be used in the study of prostate cancer[1][2].

Product Specifications

CAS Number

[19983-28-9]

Product Name Alternative

21-desDFZ-d5,21-desDFZ

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Androgen Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vpc-14228.html

Purity

99.36

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N1(C2=NC(C3=CC=CC=C3)=CS2)CCOCC1

Molecular Formula

C13H14N2OS

Molecular Weight

246.33

Precautions

H302, H315, H319, H335

References & Citations

[1]Kush Dalal, et al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289 (38) :26417-26429.|[2]Bhumireddy A, et al. Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders. Bioorg Med Chem Lett. 2022 Jan 1;55:128448.